Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bryostatin-1 Plus Paclitaxel in Advanced Gastric or GEJ Cancer
NCT00006081Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2000
- Primary completion
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bryostatin-1 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate at 8 weeks. Started Jun 2000; status: completed.
02
Drugs
bryostatin-1
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00006081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006081.